Supernus Pharmaceuticals, Inc.

This study looks at the long-term safety and effectiveness of an investigational drug called SPN-817 for adults with focal onset seizures. About 100 people who completed a previous SPN-817 study will take the drug for one year. Researchers will track side effects and changes in s…

This study tests a new medicine called SPN-817 in 60 adults whose seizures are not controlled by current treatments. The main goal is to see if the drug is safe and tolerable. Researchers will also check if it reduces the number of motor seizures per month.

This study follows 120 people with Parkinson's disease who are using a continuous apomorphine infusion pump (ONAPGO). Researchers will track how long it takes to find the right dose and how the pump affects daily symptoms and caregiver burden. The goal is to understand real-world…

This study tests a new drug called SPN-821 in 230 adults with major depressive disorder who are already taking an antidepressant but still have symptoms. Participants will receive either SPN-821 or a placebo for about a month to see if the drug safely improves depression more tha…

This study is testing an extended-release medication called SPN-812 (viloxazine) to see if it safely reduces ADHD symptoms in children aged 4 to 5 years. About 286 children will take either the drug or a placebo for 6 weeks. The main goal is to measure changes in attention and hy…